Remodeling the tumor microenvironment to unlock CAR-T cell potential

-

 

Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized hematologic cancer treatment, but its efficacy in solid tumors remains limited by poor infiltration into the complex tumor microenvironment (TME). A new review published in Volume 138, Issue 19 of the Chinese Medical Journal on October 05, 2025, outlines breakthrough strategies to address this critical bottleneck.

Solid tumors present multiple barriers: abnormal vasculature, dense extracellular matrix, disordered chemokine signals, and immunosuppressive stromal cells. These obstacles reduce CAR-T cell access to tumor cells, with circulating CAR-T levels in solid tumor patients 5–10 times lower than in hematologic cancer cases.

To tackle this, researchers are targeting vascular normalization. Anti-VEGF drugs like bevacizumab, when combined with CAR-T cells, remodel abnormal tumor blood vessels, improving T cell penetration. In preclinical models, inhibiting pathways like PAK4 or endothelial cell metabolism further enhances vascular function and CAR-T efficacy.

Modulating the chemokine system is another key strategy. Genetically engineering CAR-T cells to co-express chemokines (e.g., CCL19, CXCL10) or their receptors (e.g., CXCR6) creates targeted gradients, guiding T cells to tumors. A phase I trial of glypican-3-CAR-T cells co-expressing CCL19 and IL-7 showed promise in hepatocellular carcinoma.

Breaking physical barriers is also critical. Targeting fibroblast activation protein (FAP) on cancer-associated fibroblasts or using enzymes like hyaluronidase to degrade the extracellular matrix improves CAR-T infiltration. Preclinical studies with synNotch CAR-T cells secreting matrix-degrading enzymes have demonstrated enhanced antitumor activity.

Combination therapies amplify results: chemotherapy (e.g., nab-paclitaxel) disrupts stroma, radiotherapy triggers inflammatory signals, and oncolytic viruses remodel the TME. Local delivery methods-intratumoral injection, biomaterial scaffolds, or oxygen-releasing systems-boost CAR-T bioavailability while reducing off-target toxicity.

Despite progress, challenges persist: translating preclinical models to humans, optimizing CAR-T cell phenotypes for solid tumors, and scaling biomaterial-based delivery systems. The review emphasizes integrating immunology, genetic engineering, and materials science to advance personalized treatments.

#ResearchChemistry, #ChemicalInnovation, #Science, #ScienceResearch, #ScientificResearch, #ResearchAndDevelopment, #ChemistryEducation, #ChemistryExperiments, #ChemistryLab, #ChemistryStudents, #ChemistryStudy, #OrganicChemistry, #InorganicChemistry, #PhysicalChemistry, #AnalyticalChemistry, #Biochemistry, #MaterialsChemistry, #TheoreticalChemistry, #AppliedChemistry, #MedicinalChemistry

Comments

Post a Comment

Popular posts from this blog

Avoiding prostate cancer screening increases risk of death

-
Image
  Men who consistently avoid prostate cancer screening appointments face a disproportionately higher risk of dying from the disease, finds research identifying a new high-risk group. An analysis of data from across seven countries from the world's largest prostate cancer screening study, the European Randomized study of Screening for Prostate Cancer (ERSPC), is presented this weekend at the European Association of Urology (EAU) Congress in Madrid. Prostate cancer is the most common form of cancer in men in 112 countries, with prevalence expected to double by 2040. If introduced on a national scale, prostate cancer screening programmes that measure levels of prostate-specific antigen (PSA) in the blood have the potential to give men earlier access to treatment, a better chance of being cured. They can also prevent costly treatment associated with advanced prostate cancer. Long-term follow-up data from the ERSPC consistently report that PSA screening programmes can lead to a 20% re...
Read more

EchoBack CAR T-cells could be a game changer in cancer immunotherapy

-
Image
  Imagine a super-charged immune cell that can launch a focused attack on stubborn solid tumors - a smart fighter that destroys cancer cells for days without tiring. USC biomedical engineers have made this concept a reality, crafting what they have named the "EchoBack CAR T-cell," which could soon be a game changer in the field of cancer immunotherapy . The work, published in the scientific journal Cell, is a groundbreaking new approach that could overcome major obstacles in treating tumors that are not usually candidates for immunotherapy, while keeping healthy tissue safe. Chimeric antigen receptor (CAR) T-cell therapy is a promising field of cancer treatment that has shown great success in treating bloodborne cancers such as leukemia. It is a highly customized therapy in which cancer-fighting T-cells are drawn directly from the blood of a patient and given genetic modifications to enhance their ability to target and kill cancerous cells. The USC Alfred E. Mann Department ...
Read more

The Role of Analytical Chemistry in Industry and Manufacturing

-
Image
Industry and the manufacturing sector use multiple analytical chemical methods, whether for new product development, processing, or quality control. This article outlines the research to be presented at Pittcon on the advances being made in analytical chemistry and their application in industry and manufacturing. Spectroscopy is a valuable analytical tool for a wide range of sectors. Several talks will focus on Raman spectroscopy as a highly versatile analytical tool, which can be used in chemical processing from laboratory to manufacturing. Raman spectroscopy’s use in polymer science to measure and control chemical processes is a particular focus. The technique is becoming increasingly relevant as chemical manufacturing expands to include new developments such as batch reactions, microreactors, flow synthesis, and continuous processes. Pittcon will hear examples of using Raman spectroscopy to improve process efficiency and predict reaction end-times and physical properties of chemical...
Read more